Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays.
(2014) In Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis 38(6). p.682-690- Abstract
- B-cell lymphoma (BCL) heterogeneity represents a key issue, often making the classification and clinical management of these patients challenging. In this pilot study, we outlined the first resolved view of BCL disease heterogeneity on the protein level by deciphering disease-associated plasma biomarkers, specific for chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, using recombinant antibody microarrays targeting mainly immunoregulatory proteins. The results showed the BCLs to be heterogeneous, and revealed potential novel subgroups of each BCL. In the case of diffuse large B-cell lymphoma, we also indicated a link between the novel subgroups and survival.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4429653
- author
- Pauly, Frida
LU
; Smedby, Karin E
; Jerkeman, Mats
LU
; Hjalgrim, Henrik
; Ohlsson, Mattias
LU
; Rosenquist, Richard ; Borrebaeck, Carl A K and Wingren, Christer LU
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
- volume
- 38
- issue
- 6
- pages
- 682 - 690
- publisher
- Elsevier
- external identifiers
-
- pmid:24754901
- wos:000335919000006
- scopus:84900431021
- pmid:24754901
- ISSN
- 1873-5835
- DOI
- 10.1016/j.leukres.2014.03.010
- language
- English
- LU publication?
- yes
- id
- 12bf485a-1129-4b44-906d-73506d6c0008 (old id 4429653)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24754901?dopt=Abstract
- date added to LUP
- 2016-04-01 10:56:36
- date last changed
- 2024-01-07 04:39:16
@article{12bf485a-1129-4b44-906d-73506d6c0008, abstract = {{B-cell lymphoma (BCL) heterogeneity represents a key issue, often making the classification and clinical management of these patients challenging. In this pilot study, we outlined the first resolved view of BCL disease heterogeneity on the protein level by deciphering disease-associated plasma biomarkers, specific for chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, using recombinant antibody microarrays targeting mainly immunoregulatory proteins. The results showed the BCLs to be heterogeneous, and revealed potential novel subgroups of each BCL. In the case of diffuse large B-cell lymphoma, we also indicated a link between the novel subgroups and survival.}}, author = {{Pauly, Frida and Smedby, Karin E and Jerkeman, Mats and Hjalgrim, Henrik and Ohlsson, Mattias and Rosenquist, Richard and Borrebaeck, Carl A K and Wingren, Christer}}, issn = {{1873-5835}}, language = {{eng}}, number = {{6}}, pages = {{682--690}}, publisher = {{Elsevier}}, series = {{Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis}}, title = {{Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays.}}, url = {{https://lup.lub.lu.se/search/files/2256020/4731769}}, doi = {{10.1016/j.leukres.2014.03.010}}, volume = {{38}}, year = {{2014}}, }